Knights Of Columbus Asset Advisors LLC Coherus Bio Sciences, Inc. Transaction History

Knights Of Columbus Asset Advisors LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$2.02 - $3.14 $62,462 - $97,095	-30,922 Reduced 50.0%	30,922 $73,000
Q4 2023 Jan 31, 2024	BUY	$1.59 - $3.85 $49,165 - $119,049	30,922 Added 100.0%	61,844 $205,000
Q3 2023 Nov 01, 2023	BUY	$3.74 - $5.45 $115,648 - $168,524	30,922 New	30,922 $115,000
Q1 2021 May 17, 2021	SELL	$14.42 - $21.39 $2.1 Million - $3.12 Million	-145,647 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$16.56 - $18.94 $314 - $359	-19 Reduced 0.01%	145,647 $2.53 Million
Q3 2020 Nov 13, 2020	BUY	$17.41 - $19.89 $120,842 - $138,056	6,941 Added 5.0%	145,666 $2.67 Million
Q2 2020 Aug 14, 2020	BUY	$14.43 - $19.16 $6,349 - $8,430	440 Added 0.32%	138,725 $2.48 Million
Q1 2020 May 15, 2020	BUY	$11.67 - $22.53 $817,938 - $1.58 Million	70,089 Added 102.78%	138,285 $2.24 Million
Q4 2019 Feb 14, 2020	BUY	$16.33 - $21.37 $1.11 Million - $1.46 Million	68,196 New	68,196 $1.23 Million

130

67.8M

1.68M

91.8K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $83.2M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Knights Of Columbus Asset Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Knights Of Columbus Asset Advisors LLC with notifications on news.